For patients infected with hepatitis C virus (HCV) genotype 1 and with risk factors for treatment failure, tailoring treatment on the basis of baseline resistance-associated substitutions (RASs) status may optimize treatment efficacy, according to results published online in the Journal of Infection and Chemotherapy.
The study included 319 participants with HCV genotype 1 from a German university hospital. The researchers used population-based sequencing of NS3 and NS5A genes on each participant. Treatment was individually selected for each participant on the basis of resistance analysis.
With the treatment choice based on baseline NS3 and NS5A resistance profiles, participants across all subgroups had sustained virologic response (SVR) rates between 96% and 100%.